Literature DB >> 3595716

ATP mediates coronary vasoconstriction via P2x-purinoceptors and coronary vasodilatation via P2y-purinoceptors in the isolated perfused rat heart.

A M Hopwood, G Burnstock.   

Abstract

The effect of ATP and its analogues on the perfusion pressure of the rat coronary vasculature and the left ventricular pressure of the isolated Langendorff perfused rat heart was examined. The response to ATP was generally biphasic, causing an increase followed by a decrease in perfusion pressure. The rank order of potency of the analogues for eliciting the vasoconstriction component was alpha,beta-methyleneATP greater than 2-methylthioATP greater than ATP, which resembles the pattern previously observed for the P2x-purinoceptor. In causing vasodilation, the rank order of antagonist potency was 2-methylthioATP greater than ATP, with alpha,beta-methyleneATP being without effect; this is a characteristic of P2y-purinoceptors. 1,3-Dipropyl-8-(2-amino-4-chlorophenyl)xanthine (PACPX) antagonised some of the vasodilatory effects of ATP, showing that some of the effect is due to breakdown to adenosine. Reactive blue 2, a putative P2y-purinoceptor antagonist was found to be five times more effective at antagonising the vasodilatory responses to 2-methylthioATP than to adenosine or the vasoconstriction responses to alpha,beta-methyleneATP. We suggest that ATP exerts its biphasic effects in the coronary vasculature of the rat by interacting with P2x- and P2y-purinoceptors and partly via P1-purinoceptors after breakdown to adenosine. Reactive blue 2 was more effective at antagonising responses mediated via P2y-purinoceptors than by P2x- or P1-purinoceptors.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3595716     DOI: 10.1016/0014-2999(87)90777-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  34 in total

1.  Cibacron blue stimulation of surfactant secretion in rat type II pneumocytes.

Authors:  M Griese; L I Gobran; S A Rooney
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

2.  Purinoceptors mediating relaxation and spasm in the rat gastric fundus.

Authors:  M S Matharu; M Hollingsworth
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

3.  Expression of pannexin isoforms in the systemic murine arterial network.

Authors:  Alexander W Lohman; Marie Billaud; Adam C Straub; Scott R Johnstone; Angela K Best; Monica Lee; Kevin Barr; Silvia Penuela; Dale W Laird; Brant E Isakson
Journal:  J Vasc Res       Date:  2012-06-26       Impact factor: 1.934

4.  From one generation to the next: a comprehensive account of sympathetic receptor control in branching arteriolar trees.

Authors:  Baraa K Al-Khazraji; Amani Saleem; Daniel Goldman; Dwayne N Jackson
Journal:  J Physiol       Date:  2015-07-15       Impact factor: 5.182

Review 5.  Cardiac purinergic signalling in health and disease.

Authors:  Geoffrey Burnstock; Amir Pelleg
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

6.  Effects of pyrimidines on the guinea-pig coronary vasculature.

Authors:  A J Vials; G Burnstock
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

7.  Effects of P1 and P2Y purinoceptor antagonists on endothelium-dependent and -independent relaxations of rat mesenteric artery to GTP and guanosine.

Authors:  P Vuorinen; X Wu; P Arvola; H Vapaatalo; I Pörsti
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

Review 8.  Neuronal control of coronary blood flow.

Authors:  D Baumgart; G Heusch
Journal:  Basic Res Cardiol       Date:  1995 Mar-Apr       Impact factor: 17.165

Review 9.  Pannexin 1 in the regulation of vascular tone.

Authors:  Marie Billaud; Joanna K Sandilos; Brant E Isakson
Journal:  Trends Cardiovasc Med       Date:  2012-07-28       Impact factor: 6.677

Review 10.  Differentiating connexin hemichannels and pannexin channels in cellular ATP release.

Authors:  Alexander W Lohman; Brant E Isakson
Journal:  FEBS Lett       Date:  2014-02-15       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.